Further results showed that combined treatment of bortezomib and 3-MA or siRNA knockdown of Atg7 resulted in a marked increase in caspase 3 activation compared with the tumor cells that were treated with bortezomib alone. The gene discussed is CASP3; the disease is neoplasm.